Poor medication adherence is a pervasive issue with considerable health and
socioeconomic consequences. Although the underlying reasons are generally understood …

Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Background In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that
are more effective, shorter, and have a more acceptable side-effect profile than current …

Background Tuberculosis is usually treated with a 6-month rifampin-based regimen.
Whether a strategy involving shorter initial treatment may lead to similar outcomes is …

The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug-
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …

Background Two thirds of children with tuberculosis have nonsevere disease, which may be
treatable with a shorter regimen than the current 6-month regimen. Methods We conducted …

Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …

Tuberculosis (TB) is a major cause of morbidity and mortality worldwide. It is estimated that
25% of the world's population are infected with Mycobacterium tuberculosis, with a 5–10 …

Key Points HIV-Associated Tuberculosis Almost half of inpatients with human
immunodeficiency virus (HIV)–associated tuberculosis in countries with a high disease …

Executive summary The 2019 Lancet Commission on Tuberculosis laid out an optimistic
vision for how to build a tuberculosis-free world through smart investments based on sound …